Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, non-responders to peginterferon + ribavirin.
PMID: 27574549 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
More News: Anemia | Cirrhosis | Databases & Libraries | Gastroenterology | Hepatitis | Hepatitis C | Incivek | Study | Virology